{"organizations": [], "uuid": "6a27d1746d71bc9fc83850b5dc8bd3135b29d944", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-morphotek-announces-agreement-to-l/brief-morphotek-announces-agreement-to-license-its-eribulin-linker-payload-to-bliss-biopharmaceutical-of-china-idUSFWN1RM0P9", "country": "US", "domain_rank": 408, "title": "BRIEF-Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T17:52:00.000+03:00", "replies_count": 0, "uuid": "6a27d1746d71bc9fc83850b5dc8bd3135b29d944"}, "author": "", "url": "https://www.reuters.com/article/brief-morphotek-announces-agreement-to-l/brief-morphotek-announces-agreement-to-license-its-eribulin-linker-payload-to-bliss-biopharmaceutical-of-china-idUSFWN1RM0P9", "ord_in_thread": 0, "title": "BRIEF-Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "eikon", "sentiment": "none"}, {"name": "adcs", "sentiment": "none"}, {"name": "bliss biopharmaceutical of china reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9, 2018 / 2:55 PM / Updated 22 minutes ago BRIEF-Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China Reuters Staff \n* LICENSED ITS ERIBULIN-LINKER PAYLOAD TO BLISS BIOPHARMACEUTICAL CO OF CHINA \n* LICENSING AGREEMENT WITH BLISSBIO INCLUDES UPFRONT PAYMENT, MILESTONES, SALES ROYALTY PAYMENTS, WHICH ARE UNDISCLOSED \n* BLISSBIO HAS EXCLUSIVITY OPTION TO EXPAND TERRITORY BEYOND CHINA & TO DEVELOP THERAPEUTIC ADCS TO 2 ADDITIONAL ONCOLOGY TARGETS \n* AGREEMENT GRANTS BLISSBIO EXCLUSIVE RIGHT TO USE ERIBULIN-LINKER PAYLOAD TO DEVELOP THERAPEUTIC ADC AGAINST ONCOLOGY TARGET FOR CHINA MARKET Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-09T17:52:00.000+03:00", "crawled": "2018-04-09T18:17:40.009+03:00", "highlightTitle": ""}